Following the third UN high-level summit on non-communicable diseases last September, and with preparations for the 2019 high-level summit on Universal Health Coverage gathering speed, the World Oncology Forum (WOF) is making the case for [more]
High-income countries need to target cancer when allocating health care funds to emerging and low income countries, says Richard Sullivan, Professor of Cancer and Global Health at Kings College London. He proposes that those funding [more]
New drugs being approved for treatment of patients with cancer are providing an average of only 2.5 months of extra life, a leading researcher has told the World Oncology Forum (WOF). Tito Fojo, Professor of [more]
Global cancer programmes and projects must pay greater attention to national priorities and structures when they offer support to developing countries, says the doctor responsible for efforts to reduce women’s cancer in Zambia. Sharon Kapambwe [more]
Princess Dina Mired, President-elect of the Union for International Cancer Control (UICC) is calling on the international cancer community to change the way it supports developing countries. Princess Dina who was Director of the King [more]
Rifat Atun, Director of Global Health Systems at Harvard, warns the cancer community they must heal fragmented delivery and financing systems to tackle cancer worldwide. He summarises a seven point strategy from the World Oncology [more]
Countries across the world need to prepare for a 60% rise in cancer incidence over the next two decades. Freddie Bray Head of Cancer Surveillance at the International Agency for Research on Cancer (IARC) told [more]
The World Oncology Forum in Lugano, Switzerland, in October set a global challenge to address the growing threat from cancer in middle and low income countries. In the first of a series of short videos, [more]
At some point in this century cancer will become the leading cause of global deaths. It is already the leading cause of premature death under the age of 70 in 48 higher income countries and [more]
«Maybe in our fight against cancer we are just looking at the wrong endpoints, focusing our attention on techinicalities like the hazard ratio of a trial instead of thinking at the best way to help [more]